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INTRODUCTION: 
Neurodegenerative Disorders 
Neurodegeneration is the umbrella term for the 
progressive loss of structure or function of neurons, 
including death of neurons. Many neurodegenerative 
diseases including Parkinson‟s, Alzheimer‟s, and 
Huntington‟s occur as a result of neurodegenerative 
processes. The generation and cell death of newly 
generated cells have critical roles in brain development 
and maintenance in the embryonic and adult brain. 
Alterations in these processes are also seen in neuro-
degenerative diseases. Genes that are key players in 
neurodegenerative diseases (a-synuclein, presenilin-1, 
tau, huntingtin) are also physiologically involved in 
modulating brain plasticity. 
 
 Table 1:  Type of NeurodegenerationDisorders  
Condition Pathological Markers Main areas affected 
Alzheimer‟s disease Amyloid plaques, neurofibrillary 
tangles 
Cerebral cortex, hippocampus, basal 
nucleus of Meynert 
Lewy body dementia Lewy bodies Cerebral cortex, substantianigra, basal 
nucleus of Meynert 
Parkinson‟s disease Lewy bodies Substantianigra, dorsal motor nucleus of the 
vagus, basal nucleus of Meynert 
Vascular dementia Vascular infarctions, atherosclerosis, 
and other markers of vascular disease 
Cerebral cortex, hippocampus 
Progressive supranuclear palsy Neurofibrillary tangles Cerebral cortex, basal ganglia, spinal cord, 
midbrain 
Corticobasal degeneration Ballooned neurons with tau inclusions Cerebral cortex, basal ganglia 
Multiple system atrophy Alpha-synuclein inclusions Hindbrain structures involved in balance 
and autonomic functions 
 
Parkinson’s disease 
Parkinson‟s disease (PD) is characterised by tremor, 
rigidity, bradykinesia / akinesia and loss of postural 
reflexes. Recently non motor symptoms of PD have been 
identified and sometimes they may be the only symptom 
at onset. Basic pathology of PD relates to dopaminergic 
pathway. Many secondary causes of PD are well known.
1
 
Parkinson‟s disease (PD) is the most common disease of 
motor system degeneration and,after Alzheimer‟s 
disease, the second most common neurodegenerative 
disease.2 Parkinson‟s disease takes a heavy toll in mental 
anguish, lost productivity, and health care expenditures. 
PD prominentlyfeatures dopamine transmitter 
insufficiency and current management is almost 
exclusivelyreliant on dopamine replacement drugs. But, 
while these drugs are initially effective in most 
patients,they do not slow the underlying degeneration in 
the area of the brain most affected, thesubstantianigra 
(SN). Their effectiveness declines over time and their 
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adverse effects become increasinglymore troublesome. 
Broader options for long-term management are urgently 
needed. 3 
History:
 1 
In 1817 James Parkinson first described PD as 
“Involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; 
with a propensity to bend the trunk forwards, and to pass 
from a walking to a running pace: the senses and 
intellects being uninjured” known as shaking palsy.4 
Major criticism of this definition has been undue focus 
on muscle power and no importance to other symptoms 
like rigidity. 
Milestones in Parkinson’s disease1 
1817- J Parkinson first described “An essay on the 
shaking palsy” 
1841- Term „Paralysis agitans‟ used for the first time by 
Marshall Hall 
1888- Charcot referred the disease as “maladie de 
Parkinson” or Parkinson‟s disease 5 
1919 – Recognised PD having cell loss in substantianigra 
1939- Surgery at basal ganglia by Meyers6 
1957- Carlsson and colleagues discovered dopamine7 
1960- Ehringer and Hornykiewicz identified reduced 
dopamine in striatum8 
1961- Levodopa used for the first time in injectable form 
and a year later in oral form 
1987- Deep-brain stimulation (DBS) was first developed 
in France. 
Signs and Symptoms of Parkinson’s disease 
Parkinson‟s disease is common movement disorder 
which is characterized bythe following  
 Primary motor symptoms: 
• Bradykinesia(slowed movement) 
• Muscle rigidity (stiffness) 
• Resting tremor (shaking; usually more pronounced on 
one side of the body) 
• Postural instability (poor balance) 
 Secondary symptoms can include: 
•Micrographia (small handwriting) 
• Dysarthria (soft, muffled speech) 
• reduced arm swing on the affected side of the body 
• Short-stepped or shuffling gait 
• reduced eye blinking and frequency of swallowing 
• Depression and anxiety 
• sleep disorders 
• Low blood pressure 
• Constipation 
• Seborrhea (oily skin, dandruff) 
Major symptoms  
There are four symptoms that the majority of Parkinson‟s 
disease patients experience.  
 Rigidity: stiffness when an arm, leg, or the neck is 
moved. The muscles remain constantly tensed and 
contracted, so the person feels stiff and/or weak.  
 Resting tremor: a tremor which occurs when the 
person is at rest. This often begins with an 
occasional trembling of one hand, most obvious 
when the person is at rest or under stress. In about 
75% of cases, this tremor affects only one body part 
or side of the body initially, and then becomes more 
generalized over time.  
 Bradykinesia: slowness in initiating movement. This 
may also contribute to decreased facial movement, 
change in speech, shuffling gait and trouble with 
fine-fingered movements. Many patients find this to 
be the most frustrating aspect of their disease. It 
results in a loss of independence as it progresses, 
due to difficulties performing everyday functions, 
such as getting dressed, using utensils, and rising 
from chairs or bed.  
 Loss of postural reflexes or postural instability: 
resulting in poor balance and coordination. Patients 
sometimes develop a forward or backward lean and 
fall easily. This can also cause stooped posture, 
bowed head and drooped shoulders.  
Pathology & Pathogenesis of PD  
Neurochemical and Neuropathological 
The pathological hallmarks of PD are the loss of the 
nigrostriatal dopaminergic neurons and the presence of 
intraneuronalproteinacious cytoplasmic 
inclusions,termed “Lewy Bodies” (LBs) (Figure 1). The 
cell bodies of nigrostriatal neurons are in the SNpc, and 
they projectFamilial Neurodegenerative Diseases 
primarily to the putamen. The loss of these neurons, 
which normally contain conspicuous amounts of 
neuromelanin9, produces the classic gross 
neuropathological finding of SNpc depigmentation 
(Figure 1B). The pattern of SNpc cell loss appears to 
parallel the level of expression of the DAtransporter 
(DAT) mRNA10and is consistent with the finding that 
depletion of DA is most pronounced in the dorsolateral 
putamen11, the main site of projection for these neurons. 
At the onsets of symptoms, putamenal DA is depleted ~ 
80% and ~ 60% of SNpc dopaminergic neurons 
havealready been lost. The mesolimbic dopaminergic 
neurons, the cell bodies of which reside adjacent to the 
SNpc in the ventral tegmental area (VTA), are much less 
affected in PD12. Consequently, there is significantly less 
depletion of DA in the caudate13, the main site of 
projection for these neurons. Neuropathological studies 
of PD related neurodegeneration suggest possible clues 
to the pathogenesis of the disease. First, PD associated 
loss of dopaminergic neurons has a characteristic 
topology, distinct from the pattern seen in normal aging. 
In PD, cell loss is concentrated in ventrolateral and 
caudal portions of the SNpc, whereas during normal 
aging the dorsomedial aspect of SNpc is affected14. Thus, 
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even though age is an important risk factor for PD, the 
processes that produce age-related dopaminergic 
neuronal death are probably different from those in PD. 
Second, the degree of terminal loss in the striatum 
appears to be more pronounced than the magnitude of 
SNpc dopaminergic neuron loss11,suggesting that striatal 
dopaminergic nerve terminals are the primary target of 
the degenerative process and that neuronal death in PD 
may result from a “dying back” process. Third, the 
mechanism of synaptic DA clearance in the striatum 
seems to be more dependent on DAT than in the 
prefrontal cortex, where other monoaminergic 
transporters and the synaptic enzyme catechol-O-
methyltransferase play a greater role in terminating the 
actions ofDA 15, 16, 17. The prefrontal cortexis a primary 
site of projection for VTA dopaminergic neurons, so this 
difference may be of importance in understanding the 
relative resistance of VTA neurons to PD related 
degeneration. Differences in neuronal milieu have also 
been identified surrounding SNpc dopaminergic cell 
bodies. The neuropil of the substantianigra, compose of 
axon projections from the striatum andglobuspallidus, 
stains strongly for calbindin D28K, and most 
dopaminergic cell bodies reside within this calbin-din- 
rich neuropil18. However, the susceptible neurons in PD 
tend to be in calbindin-poor areas of the 
substantianigra19. 
Although it is commonly thought that the 
neuropathology of PD is characterized solely by 
dopaminergic neuron loss, the neurodegeneration 
extends well beyond dopaminergic neurons20. 
Neurodegeneration and LB formation are found in 
noradrenergic (locus coeruleus), serotonergic (raphe), 
and cholinergic (nucleus basalis of Meynert, dorsal 
motor nucleus of vagus) systems, as well as in the 
cerebral cortex (especially cingulate and entorhinal 
cortices), olfactory bulb, and autonomic nervous system. 
Degeneration of hippocampal structures and cholinergic 
cortical inputs contribute to the high rate of dementia that 
accompanies PD, particularly in older patients.  
However, the clinical correlates of lesions to the 
serotonergic and noradrenergic pathways are not as 
clearly characterized as are lesions in the dopaminergic 
systems. Thus, while involvement of these 
neurochemical systems is generally thought to 
occurinmore severe or late-stage disease, the temporal 
relationship of damage to specific neurochemical 
systems is not well established. For example, some 
patients develop depression months or years prior to the 
onset of PD motor symptoms, which could be due to 
early involvement of nondopaminergic pathways. In life, 
the diagnosis of PD is made on clinical grounds, but 
definite diagnosis requires the identification of both LB 
and SNpc dopaminergic neuron loss. LBs are not specific 
for PD, however, and are also found in AD, in a 
condition called “dementia with LB disease,” and as an 
incidental pathologic finding in people of advanced age 
at a greater frequency than the prevalence of PD 21. The 
role of LB in neuronal cell death is controversial, as are 
the reasons for their increased frequency in AD and the 
relationship of incidental LB to the occurrence of PD. 
LBs are spherical eosinophilic cytoplasmic protein 
aggregates composed of numerous proteins (Figure 1C), 
including α-synuclein, parkin, ubiquitin, and 
neurofilaments, and they are found in all affected brain 
regions 22,23. LBs are more than 15 μm in diameter and 
have an organized structure containing a dense hyaline 
core surrounded by a clear halo. Electron microscopy 
reveals a dense granulovesicular core surrounded by a 
ring of radiating 8–10 nm fibrils24,25. 
 
 
Figure 1:  Neuropathology of Parkinson’s disease9 
(A) Schematic representation of the normal nigrostriatal pathway (in red). It is composed of dopaminergic neurons whose cell 
bodies are located in the substantianigra pars compacta (SNpc; see arrows). These neurons project (thick solid red lines) to the 
basal ganglia and synapse in the striatum (i.e., putamen and caudate nucleus). The photograph demonstrates the normal 
pigmentation of the SNpc, produced by neuromelanin within the dopaminergic neurons. 
(B) Schematic representation of the diseased nigrostriatal pathway (in red). In Parkinson’s disease, the nigrostriatal pathway 
degenerates. There is a marked loss of dopaminergic neurons that project to the putamen (dashed line) and a much more modest 
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loss of those that project to the caudate (thin red solid line). The photograph demonstrates depigmentation (i.e., loss of dark-brown 
pigment neuromelanin; arrows) of the SNpc due to the marked loss of dopaminergic neurons. 
(C) Immunohistochemical labeling of intraneuronal inclusions, termed Lewy bodies, in a SNpc dopaminergic neuron. 
Immunostaining with an antibody against α-synuclein reveals a Lewy body (black arrow) with an intensely immunoreactive central 
zone surrounded by a faintly immunoreactive peripheral zone (left photograph). Conversely, immunostaining with an antibody 
against ubiquitin yeilds more diffuse immunoreactivity within the Lewy body (right photograph). 
 
Pathogenesis of PD 
Whatever insult initially provokes neurodegeneration, 
studies of toxic PD models and the functions of genes 
implicated in inherited forms of PD suggest two major 
hypotheses regarding the pathogenesis of the disease. 
One hypothesis posits that misfolding and aggregation of 
proteins are instrumental in the death of SNpc 
dopaminergic neurons, while the other proposes that the 
culprit is mitochondrial dysfunction and the consequent 
oxidative stress, including toxic oxidized DA species. 
The pathogenic factors cited above are not mutually 
exclusive, and one of the key aims of current PD 
research is to elucidate the sequence in which they act 
and whether points of interaction between these 
pathways are key to the demise of SNpc dopaminergic 
neurons. Potential points of interaction are diagrammed 
in Figure 2. The finding that oxidative damage to α-
synuclein can enhance its ability to misfold and 
aggregate is one example of such an interaction 26. 
Another uncertain issue is whether the multiple cell 
death-related molecular pathways activated during PD 
neurodegeneration ultimately engage common 
downstream machinery, such as apoptosis, or remain 
highly divergent. Clearly, this issue is of great 
consequence in deciding about possible therapeutic 
strategies for PD.  
Misfolding and Aggregation of Proteins 
The abnormal deposition of protein in brain tissue is a 
feature of several age-related neurodegenerative 
diseases, including PD. Although the composition and 
location (i.e., intra- or extracellular) of protein 
aggregates differ from disease to disease, this common 
feature suggests that protein deposition per se, or some 
related event, is toxic to neurons.  
Aggregated or soluble misfolded proteins could be 
neurotoxic through a variety of mechanisms. Protein 
aggregates could directly cause damage, perhaps by 
deforming the cell or interfering with intracellular 
trafficking in neurons. Protein inclusions might also 
sequester proteins that are important for cell survival. If 
so, there should be a direct correlation between inclusion 
formation and neurodegeneration. However, a growing 
body of evidence, particularly from studies of 
Huntington disease (HD) and other polyglutamine 
diseases27,28, suggests that there is no correlation between 
inclusion formation and cell death. Cytoplasmic protein 
inclusions may not result simply from precipitated 
misfolded protein but rather from an active process 
meant to sequester soluble misfolded proteins from the 
cellular milieu29. Accordingly, inclusion formation, while 
possibly indicative of a cell under attack, may be a 
defensive measure aimed at removing toxic soluble 
misfolded proteins 28,29,30,31. The ability of chaperones 
such as Hsp-70 to protect against neurodegeneration 
provoked by disease-related proteins (including α-
synuclein-mediated dopaminergic neuron loss) is 
consistent with the view that soluble misfolded proteins 
are neurotoxic 33,32. 
Mitochondrial Dysfunction and Oxidative Stress 
The possibility that an oxidative phosphorylation defect 
plays a role in the pathogenesis of PD was fueled by the 
discovery that MPTP blocks the mitochondrial electron 
transport chain by inhibiting complex I34. Subsequent 
studies identified abnormalities in complex I activity in 
PD35. In vitro studies indicate that such a complex I 
defect may subject cells to oxidative stress and energy 
failure. The abnormality of oxidative phosphorylation 
identified in PD is not confined to the brain 
36
, as reduced 
complex I activity has been found in platelets from PD 
patients 37(Parker et al., 1989) and in cybrid cells (cells 
lines engineered to contain mitochondria derived from 
platelets of PD patients 38. This latter finding suggests 
either that the observed complex I deficit is inherited 
from the mitochondrial genome or that some systemic 
toxicity leads to mutations in mitochondrial DNA. 
However, mitochondrial DNA mutations have not yet 
been identified in PD patients. 
Nearly 100% of molecular oxygen is consumed by the 
mitochondrial respiration, and powerful oxidants are 
normally produced as byproducts, including hydrogen 
peroxide and superoxide radicals. Inhibition of complex I 
increase the production of the ROS superoxide, which 
may form toxic hydroxyl radicals or react with 
nitricoxide to for mperoxynitrite. These molecules may 
cause cellular damage by reacting with nucleic acids, 
proteins, and lipids. One target of these reactive species 
may be the electron transport chain itself 39, leading to 
mitochondrial damage and further production of ROS. 
Several biological markers of oxidative damage are 
elevated in the SNpc of PD brains40. Also, the content of 
the antioxidant glutathione is reduced in the SNpc of PD 
brains41, consistent with increased ROS, although this 
could also indicate a primary reduction of protective 
mechanisms against ROS. 
The presence of ROS would increase the amount of 
misfolded proteins, increasing the demand on the 
ubquitin-proteasome system to remove them. 
Dopaminergic neurons may be a particularly fertile 
environment for the generation of ROS, as the 
metabolism of DA produces hydrogen peroxide and 
superoxide radicals, and auto oxidation of DA produces 
DA-quinone42, a molecule that damages proteins by 
reacting with cysteine residues. Mitochondria-related 
energy failure may disrupt vesicular storage of DA, 
causing the free cytosolic concentration of DA to rise 
and allowing harmful DA-mediated reactions to damage 
cellular macromolecules. Thus, DA may be pivotal in 
rendering SNpc dopaminergic neurons particularly 
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susceptible to oxidative attack. Nevertheless, despite the 
literature documenting mitochondrial dysfunction and 
indices of oxidative damage in tissue from PD patients, 
all of these observations are correlative in nature, and the 
supportive data from are correlative in nature, and the 
supportive data from that such specimens primarily 
consist of glial cells and nondopaminergic neurons, as 
most dopaminergic neurons die long before these 
specimens become available. There are no data that 
convincingly link a primary abnormality of oxidative 
phosphorylation or ROS generation with PD. 
Furthermore, Parkinsonism is rare in many diseases 
known to result from mutations directly affecting 
oxidative phosphorylation (“mitochondrial cytopathies”). 
When Parkinsonism is encountered in these diseases, it is 
generally accompanied by other symptoms not typical of 
PD. Therefore, many of the oxidative phosphorylation 
and ROS abnormalities documented in PD tissues could 
be nonspecific features of dying cells. 
 
 
Figure 2: Mechanisms of Neurodegeneration 
26
 
A growing body of evidence, detailed in this review, suggests that the accumulation of misfolded proteins is likely to be a key event in 
PD neurodegeneration. Pathogenic mutations may directly induce abnormal protein conformations (as believed to be the case with 
α-synuclein) or damage the ability of the cellular machinery to detect and degrade misfolded proteins; the role of DJ-1 remains to 
be identified. Oxidative damage, linked to mitochondrial dysfunction and abnormal dopamine metabolism, may also promote 
misfolded protein conformations. It remains unclear whether misfolded proteins directly cause toxicity or damage cells via the 
formation of protein aggregates (Lewy body). Controversy exists regarding whether Lewy bodies promote toxicity or protect a cell 
from harmful effects of misfolded proteins by sequestering them in an insoluble compartment away from cellular elements. Oxidative 
stress, energy crisis (i.e., ATP depletion) and the activation of the programmed cell death machinery are also believed to be factors 
that trigger the death of dopaminergic neurons in Parkinson’s disease. 
 
Mode of Cell Death 
How do cells ultimately die in PD? Does a common 
downstream pathway mediate all PD-related cell loss, or 
is there significant heterogeneity in the pathways 
activated in different sick neurons in a single patient, or 
among different patients with PD? The answers to these 
questions are important for the rational development of 
therapeutic strategies for PD. In programmed cell death 
(PCD), intracellular signaling pathways are activated to 
cause cell demise. Although physiological PCD is crucial 
during normal development and as a homeostatic 
mechanism in some systems (e.g., immune system), 
dysregulation of this pathway in the brain may contribute 
to neurodegeneration. Until recently, investigators have 
explored the possibility that PCD occurs in PD 
autopsyspecimens by searching for neurons that display 
features of apoptosis, a morphological correlate of PCD. 
These morphological studies have yielded conflicting 
results43. Complicating matters, if apoptosis does occur 
in PD, it may be difficult to detect by morphological 
criteria because the rate of neuronal loss may be low44 
and apoptotic cells seem to disappear rapidly45. In 
addition, there may be nonapoptotic forms of PCD46,47. 
For these reasons, some studies of PCD in PD have 
measured molecular components of PCD instead of 
relying on morphological criteria. For example, 
investigations of the PCD molecule Bax demonstrate an 
increased number of Bax-positive SNpc dopaminergic 
neurons in PD48, and compared to controls, there is 
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increased neuronal expression of Bax in PD, suggesting 
that these cells are undergoing PCD49. SNpc 
dopaminergic neurons with increased expression and 
subcellular redistribution of the anti-PCD protein Bcl-xL 
and with activated PCD effector protease caspase-3 have 
also been found in greater proportion in PD50,51. Other 
molecular markers of PCD are altered in PD, including 
the activation of caspase-852 and caspase-953. Taken 
together, these studies suggest that the PCD machinery is 
activated in postmortem PD tissue. Nevertheless, 
because these studies are single time point-descriptive 
assessments of patient tissue they cannot address whether 
the findings reflect a primary abnormality of PCD 
regulation or an appropriate “suicide” decision by injured 
cells damaged by one of the processes reviewed above. 
Current Management of Parkinson’s disease 
(Treatment): 
Drugs 
Dopa agonists: Dopa agonists can be given orally, 
intravenous or as transdermal delivery system. Oral 
dopamine agonists are ergot and non ergot derivatives. 
Bromocriptine, pergolide, piribedil, pramipexole, 
ropinorole and dihydroergocryptine are ergot 
preparations and carry a risk of long term side effects in 
form of retroperitoneal fibrosis. Pramipexol, ropinirole 
and piribedil are non ergot oral preparations. 
Apomorphine is also nonergot and used as intravenous 
route. Rotigotine and lisuride are given as transdermal 
preparations. Dopamine receptors are classified as D1, 
D2, D3, D4 and D5. Most of the dopa agonist act in PD 
through D2 and D3 receptor activity. Bromocriptine and 
pergolide are having more D2 activity where as 
ropinirole and pramipexole are having more D3 activity. 
Non motor side effects are more common with dopa 
agonists and include edema, somnolence, constipation, 
dizziness, nausea and hallucinations.54 
L- dopa (Dopamine precursor) Along with 
Decarboxylase Inhibitor : L- dopa is most important 
drug used in PD treatment. To prevent peripheral side 
effects decarboxylase inhibitor (carbidopa and 
benserazide) is combined with L- dopa. Nausea, 
vomiting and delirium are most common side effects. 
Tremor is least responsive symptoms. But most of the 
patients have significant response to the initial treatment 
and there is a marked relief in bradykinesia, rigidity and 
fatigability. However its use is limited after 5-10 years 
after onset of motor fluctuation.  
COMT Inhibitors: Catechol-O-methyltranseferase 
(COMT) metabolises L- dopa to 3-O-methyldopa. 
COMT inhibitors block this enzyme and increase plasma 
half life of L-dopa. Tolcapone and entacopone are two 
COMT inhibitors. Entacopone is available in market in 
combination with L- dopa and carbidopa. Tolcapone use 
requires continuous monitoring for liver functions. Other 
side effects are related to increase dopaminergic effects 
including sleep disturbances.  
MAO-B Inhibitors:Selegilineand rasagiline are two 
MAO-B inhibitors available for commercial use. Both 
are irreversible inhibitors. Selegiline is used as initial 
treatments option however its effect has been 
inconsistent. Rasagiline is used in a dose of 1-2 mg/day. 
It is used for motor fluctuation. They should not be given 
with tricyclic antidepressants (TCA) and selective 
serotonin reuptake inhibitors (SSRI). 
Amantidine:Amantidine is useful in PD and its 
symptoms related to dyskinesias. Mechanism of action is 
through N-methyl-D-aspartate(NMDA).It also has 
anticholinergic and dopaminomimetic action. Daily dose 
is 200mg-400mg in two divided dosages. Major side 
effects are headache, nausea and livedoreticularis. 
Anticholinergics: Most common indication of 
anticholinergic drug in PD is tremor not responding to L-
dopa.Usual dose is 0.5 mg- 6 mg in three divided 
dosages. Side effects in form of psychosis are sometimes 
serious in elderly population.  
Starting Medical Treatment in PD Patients (Dopa 
agonists or L-dopa):55There is a considerable amount of 
uncertainty while starting treatment for recently 
diagnosed patient of PD. Dopa agonists are having less 
motor fluctuation and have L-dopa sparing effect for 
initial few years of treatment. But they have some 
serious side effects in form of hallucinations and day 
time sleepiness. Their limitation is inadequate relief in 
motor symptoms in comparison to L-dopa. So they are 
considered as first line drug for young PD patients 
having mild symptoms and no dementia or other 
cognitive disorder. However they are not suitable for 
elderly and patients having dementia or severe motor 
symptoms.
 
Table 2: Herbal drugs used in Parkinson’s disease56, 57 
Plant name Family Common 
name 
Mode of use Chemical constituents 
Blepharismaderaspatensis Acanthaceae Nethirspoondu Dry seed Steroids- gomisin D 
Smilax perfoliata Smilacaceae Ram damtena Dry root Steroidal sapogeninsdiosgenin 
Smilax zeylanica Smilacaceae Rough blind 
weed,hill lotus 
Dry root Alpha, beta hydroxyl acids 
Plantagoovata Plantaginaceae Flax seed Husk fibre Mucilage, cyano genetic 
glycocydes- Linamarin, lotaustralin 
Azadirachtaindica Maliaceae Neem,margosa Fresh leaf Meliacin- nimbolide, 
quercetin, kaempferol 
Emblicaofficinalis Euphorbiaceae Amla,Indian 
goose berry 
Fruit Tannins, Phyllembelin, 
Pectins, Vitamin C 
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CONCLUSION 
This review article provides understanding of PD 
pathogenesis, provided a conceptual framework for novel 
therapies, and spawned an accelerating research effort. 
The discovery of genetic causes of PD and the 
demonstration that dysfunction of these genes probably 
plays a role in sporadic PD has highlighted the 
importance of protein misfolding-related toxicity as a 
fundamental insult in neurodegeneration. The 
identification of PD-causing genes has also demonstrated 
how dysfunction of the ubiquityin-proteasome system 
can provoke neurodegeneration, presumably by leading 
to an excess of misfolded proteins. 
This review article also provides understand the 
relationship between previously identified factors in PD 
neurodegeneration (e.g., mitochondrial dysfunction, 
ROS) and the molecular events provoked by disease 
alleles. A specific aspect of this work should be to clarify 
primary initiating events from those that may be a 
nonspecific consequence of neuronal demise. 
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